Studies past hospital records of people with acute heart failure or heart attack
Reviews records to find what triggers heart failure and how it progresses.
Plain-language title generated from the registry record
Registry title: Heart Failure-USB: Prediction and Progression
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- Cardiology, University Hospital BaselBasel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT04000061
- Record updated
- 22 September 2026
- Original description
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.Read full original descriptionShow less
Heart Failure-USB: Prediction and Progression
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.
Inclusion: Patients hospitalized with a primary diagnosis of ACS; Patients hospitalized with a primary or secondary diagnosis of AHF.
Exclusion: Existence of a documented statement of the patient against the scientific use of clinical data.